BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 20510487)

  • 1. [TNFα blocking agents and sarcoidosis: an update].
    Toussirot E; Pertuiset E
    Rev Med Interne; 2010 Dec; 31(12):828-37. PubMed ID: 20510487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
    Baughman RP; Iannuzzi M
    BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
    Nixon R; Bansback N; Brennan A
    Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
    Ortonne JP
    Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
    Régent A; Mouthon L
    Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
    Lapadula G
    Reumatismo; 2005; 57(4 Suppl):22-9. PubMed ID: 16385352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
    Denys BG; Bogaerts Y; Coenegrachts KL; De Vriese AS
    Clin Sci (Lond); 2007 Mar; 112(5):281-9. PubMed ID: 17261090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
    Ramos-Casals M; Brito-Zerón P; Muñoz S; Soto MJ;
    Medicine (Baltimore); 2008 Nov; 87(6):345-364. PubMed ID: 19011506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
    Toussirot E; Pertuiset E; Kantelip B; Wendling D
    Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
    Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
    Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
    Massara A; Cavazzini L; La Corte R; Trotta F
    Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
    Baughman RP; Lower EE; Drent M
    Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.